Takeda Ups Guidance On Mainstay Growth, Cost Discipline
Recovering underlying revenue, faster integration synergies and global portfolio growth behind upward adjustments in full-year forecasts.
You may also be interested in...
Takeda has won EU approval for an injectable version of Entyvio to treat ulcerative colitis or Crohn’s disease, in contrast to the FDA’s rejection in December.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.